Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Shanghai - Delayed Quote CNY

Shanghai Serum Bio-Technology Co., Ltd. (688163.SS)

17.41
+0.23
+(1.34%)
At close: 3:00:05 PM GMT+8
Loading Chart for 688163.SS
  • Previous Close 17.18
  • Open 17.19
  • Bid 17.38 x --
  • Ask 17.41 x --
  • Day's Range 17.18 - 17.49
  • 52 Week Range 11.50 - 22.92
  • Volume 1,059,922
  • Avg. Volume 973,607
  • Market Cap (intraday) 1.884B
  • Beta (5Y Monthly) 0.42
  • PE Ratio (TTM) 40.49
  • EPS (TTM) 0.43
  • Earnings Date --
  • Forward Dividend & Yield 0.32 (1.86%)
  • Ex-Dividend Date Sep 12, 2024
  • 1y Target Est --

Shanghai Serum Bio-Technology Co., Ltd. engages in the research, development, production, operation, and sale of antitoxin and antiserum products in China. It offers equine anti-tetanus immunoglobulin, anti-venin, and anti-rabies serum products. The company was founded in 1999 and is based in Shanghai, China.

www.serum-china.com.cn

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 688163.SS

View More

Performance Overview: 688163.SS

Trailing total returns as of 5/6/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

688163.SS
0.85%
SSE Composite Index (000001.SS)
1.06%

1-Year Return

688163.SS
18.68%
SSE Composite Index (000001.SS)
5.58%

3-Year Return

688163.SS
21.40%
SSE Composite Index (000001.SS)
10.48%

5-Year Return

688163.SS
65.18%
SSE Composite Index (000001.SS)
15.22%

Compare To: 688163.SS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 688163.SS

View More

Valuation Measures

Annual
As of 4/30/2025
  • Market Cap

    1.86B

  • Enterprise Value

    1.06B

  • Trailing P/E

    39.95

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    9.06

  • Price/Book (mrq)

    1.69

  • Enterprise Value/Revenue

    5.48

  • Enterprise Value/EBITDA

    20.02

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    23.29%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    4.13%

  • Revenue (ttm)

    194.92M

  • Net Income Avi to Common (ttm)

    45.4M

  • Diluted EPS (ttm)

    0.43

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    851.87M

  • Total Debt/Equity (mrq)

    0.40%

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: 688163.SS

View More

Company Insights: 688163.SS

Research Reports: 688163.SS

View More

People Also Watch